Literature DB >> 8957664

RNA phage Q beta coat protein as a carrier for foreign epitopes.

T M Kozlovska1, I Cielens, I Vasiljeva, A Strelnikova, A Kazaks, A Dislers, D Dreilina, V Ose, I Gusars, P Pumpens.   

Abstract

The Q beta gene C has been proposed as a new carrier for the exposure of foreign peptide sequences. Contrary to well-known 'display vectors' on the basis of coat proteins of RNA phage group I, group III phage Q beta-based vectors suggested application of the 195-amino acid extension of coat protein (CP) within the so-called A1 protein for insertion of the appropriate immunological epitopes. 'Mosaic' capsids presenting model hepatitis B virus preS1 and HIV-1 gp120 epitopes and formed by Q beta CP together with A1-derived proteins were obtained as a result of (1) suppression of leaky UGA stop codon of the CP gene and (2) simultaneous expression of 'pure' CP and full-length A1-derived genes obtained after the changing of CP-terminating UGA to strong UAA stop codon or sense GGA codon, respectively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957664     DOI: 10.1159/000150469

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  16 in total

1.  In vitro evolution and affinity-maturation with Coliphage qβ display.

Authors:  Claudia Skamel; Stephen G Aller; Alain Bopda Waffo
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

2.  Cell targeting with hybrid Qβ virus-like particles displaying epidermal growth factor.

Authors:  Jonathan K Pokorski; Marisa L Hovlid; M G Finn
Journal:  Chembiochem       Date:  2011-09-29       Impact factor: 3.164

3.  Plasma clearance of bacteriophage Qbeta particles as a function of surface charge.

Authors:  Duane E Prasuhn; Pratik Singh; Erica Strable; Steven Brown; Marianne Manchester; M G Finn
Journal:  J Am Chem Soc       Date:  2008-01-05       Impact factor: 15.419

4.  T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles.

Authors:  T Fehr; D Skrastina; P Pumpens; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 5.  Nanotechnology-based approaches for the development of diagnostics, therapeutics, and vaccines.

Authors:  Alagarsamy Srinivasan; Anshu Rastogi; Velpandi Ayyavoo; Shiv Srivastava
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-06

Review 6.  Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases.

Authors:  Pan Tao; Jingen Zhu; Marthandan Mahalingam; Himanshu Batra; Venigalla B Rao
Journal:  Adv Drug Deliv Rev       Date:  2018-07-06       Impact factor: 15.470

7.  Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds.

Authors:  Rena D Astronomo; Eiton Kaltgrad; Andrew K Udit; Sheng-Kai Wang; Katie J Doores; Cheng-Yuan Huang; Ralph Pantophlet; James C Paulson; Chi-Huey Wong; M G Finn; Dennis R Burton
Journal:  Chem Biol       Date:  2010-04-23

8.  Versatile virus-like particle carrier for epitope based vaccines.

Authors:  Alain C Tissot; Regina Renhofa; Nicole Schmitz; Indulis Cielens; Edwin Meijerink; Velta Ose; Gary T Jennings; Philippe Saudan; Paul Pumpens; Martin F Bachmann
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

9.  Assembly of hybrid bacteriophage Qbeta virus-like particles.

Authors:  Steven D Brown; Jason D Fiedler; M G Finn
Journal:  Biochemistry       Date:  2009-12-01       Impact factor: 3.162

10.  Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization.

Authors:  Caitlin D Lemke-Miltner; Sue E Blackwell; Chaobo Yin; Anna E Krug; Aaron J Morris; Arthur M Krieg; George J Weiner
Journal:  J Immunol       Date:  2020-01-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.